Healthy Volunteers
Conditions
Keywords
Erosive Esophagitis, Non-erosive Gastroesophageal Reflux Disease, Vonoprazan
Brief summary
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.
Interventions
DRUGVonoprazan ODT-1 or ODT-2 without Water
Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
DRUGVonoprazan ODT-1 or ODT-2 with Water
Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
DRUGVonoprazan (Reference)
Vonoprazan will be administered orally as a tablet
Sponsors
Phathom Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The treatment periods will include administration of single doses of vonoprazan 10 mg on Day 1 of each period. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* The participant is 18 to 55 years of age, inclusive, at Screening. * The participant has a body mass index (BMI) 18 to 32 kg/m2, inclusive, at Screening. * The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at Screening. * Female participants of reproductive potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from signing the informed consent form (ICF) until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone \[FSH\] level \>40 IU/mL during Screening). * Female participants must have a negative pregnancy test at Screening and upon Check-in. * The participant agrees to comply with all protocol requirements. * The participant is able to provide written informed consent.
Exclusion criteria
* The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening. * The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in. * The participant has a history of a clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the subject to participate. * The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (eg, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis (EE)), frequent (more than once per week) occurrence of heartburn, or any surgical intervention. * The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or ECG results that preclude his/her participation in the study, as deemed by the investigator. * The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including Cytochrome P450 3A4 (CYP3A4) inducers) except acetaminophen (up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until the end of confinement on Study Day 23. * The participant has consumed grapefruit and/or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family \[kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard\] and charbroiled meats) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study. * The participant has consumed caffeine- or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug and/or is unable to abstain through the study. * The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug. * The participant has a history of alcohol abuse and/or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake \>21 units per week for male subjects and \>14 units of alcohol per week for female subjects; 1 unit is equal to approximately ½ pint \[200 mL\] of beer, 1 small glass \[100 mL\] of wine, or 1 measure \[25 mL\] of spirits) or use of alcohol 48 hours before the first dose of study drug. * The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in. * The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study. * The participant has donated blood or blood products \>450 mL within 30 days before the first dose of study drug. * The participant has a history of relevant drug and/or food allergies (ie, allergy to vonoprazan or excipients or any significant food allergy that could preclude a standard diet in the clinical unit). * The participant has received a study drug in another investigational study within 5-times the t1/2 of the study drug or 30 days of dosing, whichever is longer. * Female participants who are pregnant or lactating; intend to become pregnant before, during, or within 4 weeks after participating in this study; or intend to donate ova during this time period. * The participant is not suitable for entry into the study in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Drug Concentration (Cmax) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | Cmax of Vonoprazan was reported. |
| Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | AUC0-t of Vonoprazan was reported. |
| AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | AUC0-inf of Vonoprazan was reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Terminal Phase Half-life (t1/2) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | t1/2 of Vonoprazan was reported. |
| Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | Tmax of Vonoprazan was reported. |
| Apparent Volume of Distribution (Vz/F) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | Vz/F of Vonoprazan was reported. |
| Apparent Oral Clearance (CL/F) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | CL/F of Vonoprazan was reported. |
| Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | Tlag of Vonoprazan was reported. |
| Terminal Elimination Rate Constant (λz) of Vonoprazan | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose | λz of Vonoprazan was reported. |
Countries
United States
Participant flow
Recruitment details
This study was conducted at single center in the United States from 14 February 2025 to 10 April 2025.
Pre-assignment details
A total of 25 healthy participants were enrolled in this 5-period crossover study and were randomized to 1 of 5 treatment sequences to receive vonoprazan as two formulations (orally dispersible tablet \[ODT\]-1 and ODT-2) with or without water. The reference formulation was vonoprazan 10 milligram (mg) tablets (Treatment E).
Participants by arm
| Arm | Count |
|---|---|
| All Participants All participants who were randomized to receive Vonoprazan 10 mg, orally, in one of the five treatment sequence: ODT-1, once on Day 1 of Period 1 without water as Treatment A, ODT-1, once on Day 1 of Period 2 mixed with water and administered via a syringe as Treatment B, ODT-2, once on Day 1 of Period 3 without water as Treatment C, ODT-2, once on Day 1 of Period 4 mixed with water and administered via a syringe as Treatment D, and Vonoprazan 10 mg tablet, once on Day 1 of Period 5 as Treatment E. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between each treatment period. | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 37.2 years STANDARD_DEVIATION 8.66 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 16 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 9 Participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 |
| other Total, other adverse events | 2 / 25 | 0 / 25 | 1 / 25 | 1 / 25 | 1 / 25 |
| serious Total, serious adverse events | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 |
Outcome results
Primary
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
AUC0-t of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 57.1 ng*hour/mL | Geometric Coefficient of Variation 45.8 |
| Treatment B: Vonoprazan 10 mg | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 54.8 ng*hour/mL | Geometric Coefficient of Variation 42 |
| Treatment C: Vonoprazan 10 mg | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 52.8 ng*hour/mL | Geometric Coefficient of Variation 41.7 |
| Treatment D: Vonoprazan 10 mg | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 51.7 ng*hour/mL | Geometric Coefficient of Variation 47.6 |
| Treatment E: Vonoprazan 10 mg | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 49.8 ng*hour/mL | Geometric Coefficient of Variation 38.5 |
90% CI: [107.46, 122.24]
90% CI: [103.14, 117.33]
90% CI: [99.39, 113.06]
90% CI: [97.39, 110.78]
90% CI: [89.99, 102.37]
90% CI: [91.87, 104.51]
Primary
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
AUC0-inf of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 59.2 ng*hour/mL | Geometric Coefficient of Variation 44.3 |
| Treatment B: Vonoprazan 10 mg | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 57.1 ng*hour/mL | Geometric Coefficient of Variation 39.4 |
| Treatment C: Vonoprazan 10 mg | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 55.3 ng*hour/mL | Geometric Coefficient of Variation 39 |
| Treatment D: Vonoprazan 10 mg | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 54.1 ng*hour/mL | Geometric Coefficient of Variation 44.9 |
| Treatment E: Vonoprazan 10 mg | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 51.9 ng*hour/mL | Geometric Coefficient of Variation 36.3 |
90% CI: [107.28, 121.17]
90% CI: [103.49, 116.9]
90% CI: [100.26, 113.24]
90% CI: [98.15, 110.86]
90% CI: [90.77, 102.53]
90% CI: [92.11, 104.05]
Primary
Maximum Observed Drug Concentration (Cmax) of Vonoprazan
Cmax of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The Pharmacokinetic (PK) population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 6.11 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 47.8 |
| Treatment B: Vonoprazan 10 mg | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 5.81 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 41.4 |
| Treatment C: Vonoprazan 10 mg | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 5.46 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 36.1 |
| Treatment D: Vonoprazan 10 mg | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 5.72 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 46.2 |
| Treatment E: Vonoprazan 10 mg | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 5.40 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 38.4 |
90% CI: [88, 102.67]
90% CI: [104.86, 122.33]
90% CI: [99.67, 116.28]
90% CI: [93.68, 109.3]
90% CI: [98.08, 114.43]
90% CI: [96.93, 113.08]
Secondary
Apparent Oral Clearance (CL/F) of Vonoprazan
CL/F of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Apparent Oral Clearance (CL/F) of Vonoprazan | 184 litres/hour (L/h) | Standard Deviation 78.9 |
| Treatment B: Vonoprazan 10 mg | Apparent Oral Clearance (CL/F) of Vonoprazan | 188 litres/hour (L/h) | Standard Deviation 76 |
| Treatment C: Vonoprazan 10 mg | Apparent Oral Clearance (CL/F) of Vonoprazan | 193 litres/hour (L/h) | Standard Deviation 72.5 |
| Treatment D: Vonoprazan 10 mg | Apparent Oral Clearance (CL/F) of Vonoprazan | 202 litres/hour (L/h) | Standard Deviation 89.2 |
| Treatment E: Vonoprazan 10 mg | Apparent Oral Clearance (CL/F) of Vonoprazan | 205 litres/hour (L/h) | Standard Deviation 75.9 |
Secondary
Apparent Volume of Distribution (Vz/F) of Vonoprazan
Vz/F of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Apparent Volume of Distribution (Vz/F) of Vonoprazan | 1930 litres (L) | Standard Deviation 735 |
| Treatment B: Vonoprazan 10 mg | Apparent Volume of Distribution (Vz/F) of Vonoprazan | 1880 litres (L) | Standard Deviation 622 |
| Treatment C: Vonoprazan 10 mg | Apparent Volume of Distribution (Vz/F) of Vonoprazan | 2030 litres (L) | Standard Deviation 678 |
| Treatment D: Vonoprazan 10 mg | Apparent Volume of Distribution (Vz/F) of Vonoprazan | 2070 litres (L) | Standard Deviation 762 |
| Treatment E: Vonoprazan 10 mg | Apparent Volume of Distribution (Vz/F) of Vonoprazan | 2100 litres (L) | Standard Deviation 668 |
Secondary
Terminal Elimination Rate Constant (λz) of Vonoprazan
λz of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0948 per hour | Standard Deviation 0.0175 |
| Treatment B: Vonoprazan 10 mg | Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0998 per hour | Standard Deviation 0.0188 |
| Treatment C: Vonoprazan 10 mg | Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0955 per hour | Standard Deviation 0.0167 |
| Treatment D: Vonoprazan 10 mg | Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0963 per hour | Standard Deviation 0.014 |
| Treatment E: Vonoprazan 10 mg | Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0975 per hour | Standard Deviation 0.0185 |
Secondary
Terminal Phase Half-life (t1/2) of Vonoprazan
t1/2 of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | Terminal Phase Half-life (t1/2) of Vonoprazan | 7.54 hours | Standard Deviation 1.36 |
| Treatment B: Vonoprazan 10 mg | Terminal Phase Half-life (t1/2) of Vonoprazan | 7.20 hours | Standard Deviation 1.42 |
| Treatment C: Vonoprazan 10 mg | Terminal Phase Half-life (t1/2) of Vonoprazan | 7.48 hours | Standard Deviation 1.38 |
| Treatment D: Vonoprazan 10 mg | Terminal Phase Half-life (t1/2) of Vonoprazan | 7.36 hours | Standard Deviation 1.22 |
| Treatment E: Vonoprazan 10 mg | Terminal Phase Half-life (t1/2) of Vonoprazan | 7.35 hours | Standard Deviation 1.36 |
Secondary
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Tmax of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: Vonoprazan 10 mg | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 hours |
| Treatment B: Vonoprazan 10 mg | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 hours |
| Treatment C: Vonoprazan 10 mg | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.12 hours |
| Treatment D: Vonoprazan 10 mg | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 hours |
| Treatment E: Vonoprazan 10 mg | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 hours |
Secondary
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan
Tlag of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Population: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: Vonoprazan 10 mg | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.32 hours |
| Treatment B: Vonoprazan 10 mg | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.25 hours |
| Treatment C: Vonoprazan 10 mg | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.32 hours |
| Treatment D: Vonoprazan 10 mg | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.25 hours |
| Treatment E: Vonoprazan 10 mg | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.27 hours |